OptoCeutics

Advancing non-invasive light technologies to stimulate the brain and improve cognitive function.

Through clinical trials, Optoceutics tests and develop solutions  to treat and diagnose neurodegenerative diseases using emerging gamma stimulation therapy and digital biomarkers.

40 Hz light for gamma stimulation has been shown to improve memory and cognitive performance in a mouse model of Alzheimer's disease. 40 Hz light stimulation reduced amyloid plaque associated with Alzheimer's disease in the brain of mice by about 50%. Optoceutics develops a masked 40 Hz light that removes the stroboscopic effect from normal stroboscopic 40 Hz light while retaining the stimulation effect on the brain. However the potential for treatment and prevention of human diseases has not yet been investigated. Clinical trials are ready to start in 2020 to validate the impact on Alzheimer's disease.